Suitable Signal Peptides for Secretory Production of Recombinant Granulocyte Colony Stimulating Factor in Escherichia Coli Publisher Pubmed



Tehrani SS^{1, 2} ; Goodarzi G^{1, 2, 3} ; Naghizadeh M^{1, 2} ; Khatami SH⁴ ; Movahedpour A^{5, 6} ; Abbasi A⁴ ; Shabaninejad Z^{7, 8} ; Khalaf N⁸ ; Taherianganeh M⁹ ; Savardashtaki A^{5, 10} Show Affiliations
Source: Recent Patents on Biotechnology Published:2020

Abstract

Background: Granulocyte colony-stimulating factor (G-CSF) expressed in engi-neered Escherichia coli (E. coli) as a recombinant protein is utilized as an adjunct to chemotherapy for improving neutropenia. Recombinant proteins overexpression may lead to the crea-tion of inclusion bodies whose recovery is a tedious and costly process. To overcome the problem of inclusion bodies, secretory production might be used. To achieve a mature secretory protein product, suitable signal peptide (SP) selection is a vital step. Objective: In the present study, we aimed at in silico evaluation of proper SPs for secretory production of recombinant G-CSF in E. coli. Methods: Signal peptide website and UniProt were used to collect the SPs and G-CSF sequenc-es. Then, SignalP were utilized in order to predict the SPs and location of their cleavage site. Physicochemical features and solubility were investigated by ProtParam and Protein-sol tools. Fusion proteins sub-cellular localization was predicted by ProtCompB. Results: LPP, ELBP, TSH, HST3, ELBH, AIDA and PET were excluded according to SignalP. The highest aliphatic index belonged to OMPC, TORT and THIB and PPA. Also, the highest GRAVY belonged to OMPC, ELAP, TORT, BLAT, THIB, and PSPE. Furthermore, G-CSF fused with all SPs were predicted as soluble fusion proteins except three SPs. Finally, we found OMPT, OMPF, PHOE, LAMB, SAT, and OMPP can translocate G-CSF into extracellular space. Conclusion: Six SPs were suitable for translocating G-CSF into the extracellular media. Alt-hough growing data indicate that the bioinformatics approaches can improve the precision and ac-curacy of studies, further experimental investigations and recent patents explaining several in-ventions associated to the clinical aspects of SPs for secretory production of recombinant G-CSF in E. coli are required for final validation. © 2020 Bentham Science Publishers.